In a neoadjuvant-resistant case of breast cancer, the PMCA level was dramatically higher than that in a neoadjuvant-sensitive case, independent of ER status (estrogen receptor positive/negative, ER+/−) (Fig. 6G, H). The gene discussed is ESR1; the disease is breast carcinoma.